Massively Parallel Screening of Toll/Interleukin‐1 Receptor (TIR)‐Derived Peptides Reveals Multiple Toll‐Like Receptors (TLRs)‐Targeting Immunomodulatory Peptides
Advanced Science · 2025
DOI: 10.1002/advs.202406018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yun Lim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Natural Product Research Center, Korea Institute of Science and Technology, Gangneung, 25451, Republic of Korea. Hauptthemen laut MEDLINE: Toll-Like Receptors, Peptides, Receptors, Interleukin-1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Institute of Science and Technology, National Research Foundation of Korea.
Abstract (Originalsprache)
Toll‐like receptors (TLRs) are critical regulators of the immune system, and altered TLR responses lead to a variety of inflammatory diseases. Interference of intracellular TLR signaling, which is mediated by multiple Toll/interleukin‐1 receptor (TIR) domains on all TLRs and TLR adapters, is an effective therapeutic strategy against immune dysregulation. Peptides that inhibit TIR‐TIR interactions by fragmenting interface residues have potential as therapeutic decoys. However, a systematic method for discovering TIR‐targeting moieties has been elusive, limiting exploration of the vast, unsequenced space of the TIR domain family. A comprehensive parallel screening method is developed to uncover novel TIR‐binding peptides derived from previously unexplored surfaces on a wide range of TIR domains. A large peptide library is constructed, named TIR surfacesome, by tiling surface sequences of the large TIR domain family and screening against MAL TIR and MyD88 TIR , TIRs of two major TLR adaptor proteins, resulting in the discovery of hundreds of TIR‐binding peptides. The selected peptides inhibited TLR signaling and demonstrated anti‐inflammatory effects in macrophages, and therapeutic potential in mouse inflammatory models. This approach may facilitate the development of TLR‐targeted therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Natural Product Research Center, Korea Institute of Science and Technology, Gangneung, 25451, Republic of Korea.
- Natural Product Informatics Research Center, Korea Institute of Science and Technology, Gangneung, 25451, Republic of Korea.
- Department of Bioinformatics and Life Science, Soongsil University, Seoul, 06978, Republic of Korea.
- Department of Convergence Medicine, Yonsei University Wonju College of Medicine, Wonju, 26426, Republic of Korea.
- Department of YM-KIST Bio-Health Convergence, Yonsei University, Wonju, 26493, Republic of Korea.
ORCID-Profile: Moon-Hyeong Seo
Förderung
- Korea Institute of Science and Technology
- National Research Foundation of Korea
Zitieren
APA
Lim, Y., Kang, T. K., Kim, M. I., Kim, D., Kim, J. Y., Jung, S. H., Park, K., Lee, W. B., & Seo, M. H. (2025). Massively Parallel Screening of Toll/Interleukin‐1 Receptor (TIR)‐Derived Peptides Reveals Multiple Toll‐Like Receptors (TLRs)‐Targeting Immunomodulatory Peptides. Advanced Science. https://doi.org/10.1002/advs.202406018
Vancouver
Lim Y, Kang TK, Kim MI, Kim D, Kim JY, Jung SH, et al. Massively Parallel Screening of Toll/Interleukin‐1 Receptor (TIR)‐Derived Peptides Reveals Multiple Toll‐Like Receptors (TLRs)‐Targeting Immunomodulatory Peptides. Advanced Science. 2025. doi:10.1002/advs.202406018
BibTeX
@article{Lim2025,
author = {Lim, Yun and Kang, Tae Kyeom and Kim, Meong Il and Kim, Dohyeon and Kim, Ji Yul and Jung, Sang Hoon and Park, Keunwan and Lee, Wook-Bin and Seo, Moon-Hyeong},
title = {Massively Parallel Screening of Toll/Interleukin‐1 Receptor (TIR)‐Derived Peptides Reveals Multiple Toll‐Like Receptors (TLRs)‐Targeting Immunomodulatory Peptides},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202406018}
}
EUVIMED